| Literature DB >> 18500986 |
Richard J MacIsaac1, Merlin C Thomas, Sianna Panagiotopoulos, Trudy J Smith, Huming Hao, D Geoffrey Matthews, George Jerums, Louise M Burrell, Piyush M Srivastava.
Abstract
BACKGROUND: In comparison to the well established changes in compliance that occur at the large vessel level in diabetes, much less is known about the changes in compliance of the cardiovascular system at the end-organ level. The aim of this study was therefore to examine whether there was a correlation between resistance of the intrarenal arteries of the kidney and compliance of the left ventricle, as estimated by measurements of diastolic function, in subjects with type 2 diabetes.Entities:
Mesh:
Year: 2008 PMID: 18500986 PMCID: PMC2413205 DOI: 10.1186/1475-2840-7-15
Source DB: PubMed Journal: Cardiovasc Diabetol ISSN: 1475-2840 Impact factor: 9.951
Clinical and biochemical parameters for 167 subjects with type 2 diabetes, stratified according to cardiac function
| Total cohort (n = 167) | Normal cardiac function (n = 59) | Diastolic dysfunction alone (n = 66) | Diastolic and systolic dysfunction (n = 30) | |
| Intrarenal RI | 0.69 ± 0.01 | 0.66 ± 0.06 | 0.72 ± 0.06** | 0.71 ± 0.06** |
| Age (years) | 62 ± 12 | 55 ± 13 | 66 ± 9* | 66 ± 12* |
| Sex (% male) | 59% | 59% | 54% | 72% |
| Diabetes duration (years) | 11 ± 8 | 9 ± 6 | 13 ± 8* | 10 ± 7 |
| Obese BMI (>30 kg/m2, %) | 57% | 48% | 60% | 56% |
| History of CVD (%) | 36% | 23% | 32% | 69%* |
| HbA1c (%) | 7.7 ± 1.5 | 8.1 ± 1.5 | 7.6 ± 1.3* | 7.4 ± 1.9* |
| Metformin use(%) | 68% | 80% | 55%* | 69% |
| Sulphonylurea use (%) | 57% | 62% | 50% | 72% |
| Glitazone use (%) | 19% | 31% | 11%* | 17% |
| Insulin use (%) | 42% | 45% | 46% | 24% |
| Hypertension (%) | 81% | 69% | 85%* | 90%* |
| Systolic BP (mmHg) | 140 ± 17 | 135 ± 17 | 144 ± 18 | 141 ± 15 |
| Diastolic BP (mmHg) | 75 ± 8 | 76 ± 8 | 74 ± 8 | 76 ± 9 |
| RAS inhibitor use (%) | 72% | 54% | 84%* | 83%* |
| Number of antihypertensives (n) | 1.9 ± 1.4 | 1.3 ± 1.3 | 2.1 ± 1.4* | 2.7 ± 1.5* |
| Total cholesterol (mM) | 4.7 ± 0.9 | 4.9 ± 1.0 | 4.8 ± 0.8 | 4.6 ± 1.0 |
| Triglycerides (mM) | 2.1 ± 1.2 | 2.3 ± 1.3 | 2.0 ± 1.1 | 2.3 ± 1.4 |
| Treatment for dyslipidaemia | 63% | 58% | 53% | 90%* |
| History of retinopathy | 27% | 14% | 44%* | 17% |
| iGFR (ml/min/1.73 m2) | 93 ± 32 | 111 ± 27 | 82 ± 27* | 73 ± 30* |
| GFR< 60 (ml/min/1.73 m2) | 22% | 6% | 25%* | 39%* |
| AER > 20 (μg/min) | 45% | 41% | 39% | 59%* |
Data for continuous variables are mean ± SD. Data for categorical variables are expressed as proportions.
* p < 0.05, ** p < 0.01 vs individuals with normal cardiac function on TTE,
Figure 1Intrarenal resistance index values in subjects with type 2 diabetes, stratified according to cardiac function on a transthoracic echocardiogram. ○ denotes individuals with normal cardiac function. △ denotes individuals with diastolic dysfunction alone. ♦ denotes individuals with diastolic and systolic dysfunction. ** P < 0.01 vs normal transthoracic echocardiogram.
Figure 2Correlations between the intrarenal resistance index and markers of diastolic dysfunction, i.e., (A) the E/Vp ratio (r = 0.41, p < 0.001) and (B) left atrial area (r = 0.36, p < 0.001). Solid lines denote the linear regression relationship between the variables. The dotted lines denote the 95% confidence interval for the regression relationship.